Vaccine News and Research

Latest Vaccine News and Research

WHO declares end of H1N1 pandemic

"World Health Organisation Director-General Margaret Chan announced Tuesday the end of the [H1N1] swine flu pandemic, more than a year after it was declared," Agence France-Presse reports. "The world is no longer in phase 6 of influenza pandemic alert. We are now moving into the post-pandemic period," Chan said during a virtual press conference from Hong Kong, according to a WHO press release (8/10).

11 Aug 2010

NIAID launches clinical trials of dengue vaccine

After more than a decade of development, the National Institute of Allergy and Infectious Diseases (NIAID) has started clinical trials to test a vaccine to protect against the dengue virus, a product researchers hope may one day "help prevent a disease to which 2.5 billion people are exposed," CIDRAP News reports (Roos, 8/9).

11 Aug 2010

Opinions: HIV prevention research; Foreign aid; Sanitation; Aid, self-reliance

"Microbicides, vaccines and other new approaches will one day join proven HIV-prevention strategies, including condoms, male circumcision and clean needles. How soon that day comes will depend on whether funders and the scientific community can develop the more collaborative approaches to HIV prevention research needed to address this fast-moving epidemic," Global HIV Vaccine Enterprise leaders Alan Bernstein, executive director, and Peter Piot, chair, write in a Globe and Mail opinion piece.

11 Aug 2010

Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting

New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.

10 Aug 2010

Cancer Research Technology grants Scancell licence to use 105AD7 human antibody

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, and Cancer Research Technology Ltd - Cancer Research UK's commercialisation and development arm - today announce that they have signed an agreement under which Scancell has been granted a licence to use a human antibody known as 105AD7.

10 Aug 2010

Texas Children's Hospital provides tips to ensure healthy and successful school year

It's August and for many families that means it's time to head back to school. From sleep schedules, nutrition, immunizations, heart health, heat illnesses and more, Texas Children's Hospital in Houston provides parents with tips to ensure their children have a safe, healthy and successful school year.

10 Aug 2010

NIH begins human clinical testing for dengue virus vaccine

After more than a decade of development at the National Institutes of Health, a vaccine to prevent infection by the mosquito-borne dengue virus has begun human clinical testing. The vaccine was developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID) and is undergoing clinical study at the Johns Hopkins Bloomberg School of Public Health in Baltimore.

10 Aug 2010

Scientists work towards creating a vaccine for Parkinson's disease

Nina Brown, 68, and millions of others with a debilitating neurological condition called Parkinson's disease are counting on researchers for a cure. At The University of Texas Health Science Center at Houston (UTHealth), protein chemists are working to develop a therapeutic vaccine.

10 Aug 2010

Lentigen receives NIH SBIR grant for program on clinical vector for TCR immunotherapy targeted to melanoma

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) Small Business Innovation Research grant (SBIR) for a program on "Clinical Vector for TCR Immunotherapy Targeted to Melanoma". In this program, Lentigen will collaborate with Dr. Michael Nishimura, Professor of Surgery, at the Medical University of South Carolina (MUSC).

9 Aug 2010

Intellect Neurosciences receives Notice of Allowance for new OXIGON patent in Canada

Intellect Neurosciences, Inc announced that it has received a Notice of Allowance from the Canadian Patent and Trademark Office for a new patent related to OX1 (OXIGON™), the Company's clinical-stage drug candidate that has disease-modifying potential for Alzheimer's and other neurodegenerative disorders. OX1 is an orally-administered, brain-penetrating, naturally-occurring, copper-binding small molecule targeting multiple mechanisms that contribute significantly to the underlying pathology of Alzheimer's disease.

9 Aug 2010

An overview of SRVP annual meeting

Islamic countries have acknowledged the importance of self-reliance in vaccine production and are committed to establishing closer cooperation towards achieving it, as they ended their 6th Annual Meeting of Self-Reliance in Vaccine Production (SRVP), in Bandung, Indonesia.

9 Aug 2010

Anti-viral drug addition to standard treatment regimen increases cure rate for hepatitis C

Adding a direct acting anti-viral drug to the standard treatment regimen for hepatitis C significantly increases the cure rate in the most difficult to treat patients, according to a research report published Monday in the online edition of the journal The Lancet.The research team, led by Paul Kwo, M.D., of Indiana University School of Medicine, reported that adding the drug nearly doubled the treatment's effectiveness when given for 48 weeks in one treatment arm of the study.

9 Aug 2010

Genetic factors lead to meningitis development: Study

Genetic differences that make some people susceptible to developing meningococcal meningitis and septicaemia, and others naturally immune, are revealed in a new study of over 6,000 people, published today in Nature Genetics.The research, led by Imperial College London and the Genome Institute of Singapore, is the largest ever genetic study of meningitis and septicaemia caused by meningococcal bacteria. It suggests that people who develop these diseases have innate differences in their natural defences that leave them unable to attack meningococcal bacteria successfully.

9 Aug 2010

Hemispherx Biopharma second-quarter net loss decreases to $3.67 million

Hemispherx Biopharma, Inc. announced its financial results for the three months ended June 30, 2010. The net loss (including non-cash expenses) for the 2nd fiscal quarter was approximately $3,676,000 or $0.03 per share compared to a loss of approximately $3,870,000 or $0.04 per share for the same period in 2009.

7 Aug 2010

Clinical trials in Asia, Africa confirm safety, effectiveness of rotavirus vaccine

Two studies published online Thursday in the Lancet show that the rotavirus vaccine is safe and effective at preventing much of the gastrointestinal illness in developing countries, where rotavirus kills more than 400,000 children under age 5 annually, Reuters reports. Based on the findings in Asia and Africa, the studies' authors "urged the governments of developing nations to make the vaccines a priority," the news service writes.

7 Aug 2010

Novavax reports net loss of $9.4M for second-quarter 2010

Novavax, Inc. today announced financial results for the second quarter ended June 30, 2010.

7 Aug 2010

Recent releases in Global Health

According to a Lancet Comment, "alcohol remains conspicuously absent from the larger field of research and programming in HIV and substance use. ... Patterns of hazardous alcohol consumption prevail in countries with the most severe HIV epidemics, notably eastern and southern Africa." In addition, "hazardous drinking patterns also dominate in the concentrated epidemics of eastern Europe and Asia, where alcohol use by injecting drug users and other marginalised groups might be an additional barrier to effective efforts to prevent HIV infection."

7 Aug 2010

Nabi Biopharmaceuticals reports revenue of $4.8M for second-quarter 2010

Nabi Biopharmaceuticals today announced its second quarter financial results for the three month period ended June 26, 2010. The Company reported a net loss from continuing operations of $3.4 million, or $0.08 per share, compared to a net loss of $5.8 million, or $0.11 per share, for the period ended June 27, 2009.

6 Aug 2010

Clinton, Shah discuss long-term help, disease monitoring in Pakistan after flooding

After flooding in northwest Pakistan killed more than 1,500 people and displaced an estimated 300,000, leaders of the State Department and USAID are "promising an extended mission to deal with the long-term effects," Foreign Policy's "The Cable" blog reports. Secretary of State Hillary Rodham Clinton and USAID Administrator Rajiv Shah briefed reporters Wednesday about the disaster and their agencies' efforts in the region (Rogin, 8/4).

6 Aug 2010

Helmsley Charitable Trust awards $3.15M grant to support UofL James Graham Brown Cancer Center

The University of Louisville has received a $3.15 million grant from the Leona M. and Harry B. Helmsley Charitable Trust to support the UofL James Graham Brown Cancer Center and cancer research taking place in Owensboro. The grant will be matched with state "Bucks for Brains" funding to bring more than $4.5 million to the Owensboro Cancer Research Program.

6 Aug 2010

Vaccine News and Research

Latest Vaccine News and Research

WHO declares end of H1N1 pandemic

NIAID launches clinical trials of dengue vaccine

Opinions: HIV prevention research; Foreign aid; Sanitation; Aid, self-reliance

Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting

Cancer Research Technology grants Scancell licence to use 105AD7 human antibody

Texas Children's Hospital provides tips to ensure healthy and successful school year

NIH begins human clinical testing for dengue virus vaccine

Scientists work towards creating a vaccine for Parkinson's disease

Lentigen receives NIH SBIR grant for program on clinical vector for TCR immunotherapy targeted to melanoma

Intellect Neurosciences receives Notice of Allowance for new OXIGON patent in Canada

An overview of SRVP annual meeting

Anti-viral drug addition to standard treatment regimen increases cure rate for hepatitis C

Genetic factors lead to meningitis development: Study

Hemispherx Biopharma second-quarter net loss decreases to $3.67 million

Clinical trials in Asia, Africa confirm safety, effectiveness of rotavirus vaccine

Novavax reports net loss of $9.4M for second-quarter 2010

Recent releases in Global Health

Nabi Biopharmaceuticals reports revenue of $4.8M for second-quarter 2010

Clinton, Shah discuss long-term help, disease monitoring in Pakistan after flooding

Helmsley Charitable Trust awards $3.15M grant to support UofL James Graham Brown Cancer Center

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in